Almirall 9M 2026 Results

Impact · against what's priced in

Almirall's 9M 2026 results demonstrate strong operating leverage with EBITDA growth significantly outpacing revenue growth. The reiteration of full-year guidance provides stability, while the 24.9% margin indicates efficient scaling of its dermatology business.

ALM+0.60

No priced-in read yet

In context

Net sales grew 8.3% to €889.2 MM, but the 22.7% surge in EBITDA to €221.7 MM reveals substantial operating leverage and a strong 24.9% margin.

Read from the article alone

• guidance▲16%
• earnings▲4%
• healthcare▲2%
• pharmaceuticals
• ALM
• dermatology
• spain